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Available online 16 April 2016Regulatory guidance for schizophrenia cognition clinical trials requires that the assessment of cognitive change is
accompanied by a functionally meaningful endpoint. However, currently available measures are challenged by
resistance to change, psychometric weaknesses, and for interview-based assessments, dependence upon the
presence of an informant. The aims of the current study were to: 1) assess the validity, sensitivity, and reliability
of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) as ameasure of functional capacity; 2) deter-
mine the association between performance on the VRFCAT and performance on the MATRICS Consensus Cogni-
tive Battery (MCCB); and 3) compare the metrics of the VRFCAT with the UCSD Performance-based Skills
Assessment (UPSA). 167 patients with schizophrenia and 166 healthy controls completed the VRFCAT, UPSA,
and the MCCB at baseline. The VRFCAT and UPSA were completed again at follow-up. The VRFCAT, MCCB, and
UPSAwere very sensitive to impairment in schizophrenia (d=1.16 to 1.22). High test-retest reliabilitywas dem-
onstrated for VRFCAT total completion time and theUPSA total score in patients (ICC=0.81 and 0.78, respective-
ly). The UPSA demonstrated signiﬁcant practice effects in patients (d = 0.35), while the VRFCAT did not
(d=−0.04). VRFCAT total completion time was correlated with both UPSA (r=−0.56, p b 0.0001 for patients
and −0.58, p b 0.0001 for controls) and MCCB Composite (r = −0.57, p b 0.0001 for patients and −0.68,
p b 0.0001 for controls). The VRFCAT is a highly reliable and sensitive measure of functional capacity with
associations to the UPSA and MCCB. These results provide encouraging support for a computerized functional
capacity assessment for use in schizophrenia.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Everyday functioning1. Introduction
Schizophrenia is a serious mental illness accompanied by cognitive
impairment that persists over the lifetime (Bilder et al., 2000; Harvey
et al., 1999; Saykin et al., 1994; Seidman et al., 2010). Cognitive impair-
ment is a substantial determinant of the adverse functional conse-
quences of the disorder, such as the inability to live independently,
maintain interpersonal relationships, and work (Bowie and Harvey,
2005; Leifker et al., 2009). Unfortunately, current antipsychotics provide
onlyminimal cognitive beneﬁt (Davidson et al., 2009; Keefe et al., 2007).
Substantial research is focused on attempting to discover treatments
aimed at improvement of cognitive functioning for patients with schizo-
phrenia. A consensus initiative, the Measurement and Treatment Re-
search to Improve Cognition in Schizophrenia (MATRICS) projectCenter, Box 3270, Durham, NC
.
. This is an open access article under(Marder and Fenton, 2004), was aimed at the unmet need for standard-
izedmethods for development of treatments of cognitive impairment as-
sociated with schizophrenia. During this work, the FDA representatives
stated their position, consistent with earlier guidance (Laughren, 2001)
that cognitive improvements alone are not a sufﬁcient demonstration
of treatment efﬁcacy and that approval of new treatments for cognitive
impairments would also require evidence that any cognitive improve-
ments were clinically meaningful. Thus, in the US and likely elsewhere,
clinical trials for cognitive enhancement in schizophrenia must demon-
strate improvement on a standard cognitive measure and improvement
on a measure aimed at indexing meaningful current or potential beneﬁt
to the patient's functioning. This is known as a ‘co-primary requirement’.
The MATRICS project leaders made very speciﬁc recommendations
aboutwhich standard cognitivemeasureswould validlymeasure cogni-
tive change, and developed a battery of tests for this purpose known as
the MATRICS Consensus Cognitive Battery (Nuechterlein et al., 2008).
However, they recommended that a change in real-world functioning
should not be a requirement of drug approval. Their reasoning wasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nia, such as maintaining employment, living independently, and main-
taining social relationships. However, changes in these aspects of real-
world functioning might not be observed in treatment studies because
they are likely to take longer to occur, even in the presence of cognitive
gains, than the duration of a typical clinical trial. Furthermore, real-
world functional change is dependent upon a variety of circumstances
unrelated to treatment, such as the local and national economies, state
funding, and whether a patient is receiving disability payments
(Rosenheck et al., 2006). The MATRICS group thus recommended that
clinical meaningfulness could be demonstrated through assessment of
the potential to demonstrate real-world functional improvements asso-
ciated with cognitive change (Green et al., 2008). Such outcomes are
currently referred to as measures of “functional capacity” (Moore
et al., 2007). These measures are important not only for treatment de-
velopment, but also for the collection of outcome data and clinical treat-
ment response.
The Validation of Intermediate Measures study (Green et al., 2011)
conducted a head to head comparison of several interview and
performance-based assessments of functional capacity. Interview-
based assessments solely reliant on patient self-report were found to
manifest minimal correlation with performance on the MATRICS
Consensus Cognitive Battery (MCCB). Other studies using high contact
informants have found higher cross-sectional correlations and greater
sensitivity to treatment (Durand et al., 2015; Keefe et al., 2015a;
Sabbag et al., 2011). However, many patients do not have someone
who could reliably observe cognitively relevant behaviors, which
could prevent enrollment of such patients in clinical trials. In contrast,
performance-based assessments of functional capacity do not require
informants. Further, the test most frequently used tomeasure function-
al capacity in schizophrenia clinical trials, the UCSD performance based
skills assessment (UPSA), has been found repeatedly to manifest sub-
stantial cross-sectional correlationswith cognition (Leifker et al., 2011).
The UPSA and other previous performance-based functional capaci-
ty measures have typically involved pen and paper methods, with re-
quirements for patients to role-play the performance of certain tasks.
Some of the critical tasks in these assessments also require functional
activities that are becoming outdated (calling directory assistance or
writing a paper check) or that are easily learned and susceptible to prac-
tice effects because there is only one form of the test. Some components
of the tasks are challenging to validly adapt to cross national/cross-
cultural trial designs (Velligan et al., 2012). As the UPSA is designed to
detect disability and not to generate a normal distribution of scores ref-
erenced to healthy performance, there is also the potential for a propor-
tion of patients to obtain valid baseline scores that are so high that they
cannot improve with treatment.
In an attempt to enhance the assessment of functional capacity, we
have developed a computerized, immersive (i.e., generating a three-
dimensional image that appears to surround the user), and potentially
remotely deliverable assessment referred to as the Virtual Reality Func-
tional Capacity Assessment Tool (Atkins et al., 2015; Ruse et al., 2014).
The VRFCAT consists of 6 versions of 4 mini scenarios that include navi-
gating a kitchen and planning a trip to the grocery store, catching a bus
to and from the store (selecting the correct bus and paying the correct
fare), shopping for and purchasing the correct items at the store, and
returning home. Thus, this assessment strategy captures several of the
domains of other functional capacitymeasures: transportation, ﬁnances,
householdmanagement, and planning. The alternate forms are a unique
feature of this assessment and the scenarios have the potential to be up-
dated and cross-culturally adapted in geographical regions where com-
puter use, public transportation, and grocery stores are common.
The current study evaluated the psychometric characteristics of the
VRFCAT, with special reference to correlations with the MCCB and the
leading co-primary measures used in schizophrenia clinical trials, the
UPSA and the Schizophrenia Cognition Rating Scale (SCoRS). Following
the processes by which the MATRICS-CT group evaluated co-primarymeasures, we evaluated the characteristics of the VRFCAT in terms of
the following areas: sensitivity to impairment; test-retest reliability;
practice effects; relationship to cognitive impairment; relationship to
real-world functioning; and tolerability for patients. We also investigat-
ed the relationship of the VRFCAT to key demographics and symptoms,
and compared the alternate forms of the VRFCAT for similarity.
2. Experimental/materials and methods
2.1. Participants
Schizophrenia patients and healthy controls were recruited at three
research sites: 1) TheUniversity of South Carolina under the supervision
of Dr. Meera Narasimhan; 2) The University of Miami Miller School of
Medicine under the supervision of Dr. Philip Harvey; and 3) The Univer-
sity of California, San Diego School of Medicine under the supervision of
Dr. Thomas Patterson.
Patients met criteria for DSM-IV TR schizophrenia, any subtype. All
patients completed a structured diagnostic interview, administered by
a trained interviewer: the Mini International Neuropsychiatric Inter-
view, 6th Edition (Sheehan et al., 1998). Patients with PANSS symptom
severity scores N5 (“moderately severe”) on either item P1 or P3 (delu-
sions or hallucinatory behavior) were excluded from the study, in line
with the standards for cognitive enhancement clinical trials from the
MATRICS initiative (Buchanan et al., 2011, 2005). Patients were also
screened for their ability to engage in testing. Those who were uncoop-
erative, suffered fromextreme cognitive impairment, had anotherDSM-
IV diagnosis that would exclude the diagnosis of schizophrenia, or had
severely limited eyesight were excluded. Participants who participated
in studies of cognition with any of the same measures within the last
12 months were not included. None of the participants in our previous
feasibility study of the (Ruse et al., 2014) were included. Healthy con-
trols were excluded for a lifetime history of a psychotic disorder, bipolar
disorder, or major depression. Other exclusionary criteria for both sam-
ples included inability to provide personal informed consent, history of
brain trauma, documented neurologic disorder, medical conditions in-
terfering with daily functioning, and current or recent substance
abuse. Approval from the Institutional Review Board (IRB) was secured
at each site and at the Sponsor site and all patients and healthy controls
signed an IRB approved consent form.
2.2. VRFCAT description
TheVRFCATmeasures four different functional abilities: checking for
the availability of items to complete a recipe, taking a bus, shopping in a
store, and managing currency. These scenarios use immersive comput-
erized technology. All participants received a brief tutorial, which
included sample items similar to those from the test and practice in
using the mouse and computer. There were 12 different objectives,
presented in Table 1. For each objective the dependent variables were
accuracy of performance and time to completion. For all objectives, par-
ticipants who were unable to complete the objective within a pre-
speciﬁed time period were given a time to completion score of 300 s
for that objective and automatically progressed to the next objective.
Progressions were scored in a binary fashion with 1 indicating the sub-
ject was progressed to the next objective at least once during the testing
period. All subjects completed a VRFCAT questionnaire that asked them
to rate pleasantness, ease of use, clarity of instructions and realismof the
VRFCAT virtual environment on a 7-point Likert scale. Six different
forms of the VRFCAT were developed and tested in this study.
2.3. Convergent validity assessments
2.3.1. MATRICS Consensus Cognitive Battery (MCCB)
TheMCCBmeasures seven separable cognitive domains: speed of pro-
cessing; attention/vigilance; working memory (verbal and nonverbal);
Table 1
Objectives of the VRFCAT.
Mini scenario Objective
Apartment 1. Pick up the recipe on the counter
2. Search for ingredients in your cabinets and refrigerator
3. Access your recipe and cross off the ingredients that you
already have in your apartment. When you are ﬁnished
crossing off the ingredients, pick up the bus schedule on the
counter
4. Pick up the billfold on the counter
5. Exit the apartment and head to the bus stop
Bus to store 6. Wait for the correct bus to the grocery store and then board it
when it arrives
7. Add up the exact amount of bus fare in your hand and pay for
the bus
Store 8. Select a food aisle to begin shopping
9. Continue shopping for the necessary food ingredients, and
when ﬁnished check out
10. Add up the exact amount for your purchase in your hand and
pay for groceries
Bus to
apartment
11. Wait for the correct bus to your apartment and then board it
when it arrives
12. Add up the exact amount of bus fare in your hand and pay for
the bus
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cial cognition. Administration of the MCCB requires about 75–90 min.
The subtests were administered in the standard order. The MCCB scoring
program yields seven domain scores and a composite score, which are
standardized to the same T-score measurement scale with a mean of 50
and an SD of 10 (Kern et al., 2008).
2.3.2. Functional capacity
We used the same version of the UPSA that was used in the
MATRICS-CT Validation of Intermediate Measures study (UPSA-VIM)
(Sabbag et al., 2011). The UPSA-VIM was designed to assess the ability
to perform everyday tasks needed for independent community func-
tioning. The UPSA-VIM evaluates ﬁve areas: household chores, commu-
nication,ﬁnance, transportation, and organization/planning. Raw scores
from each subtest are transformed to yield comparable scores (ranging
from 0 to 20) for each and a summary score ranging from 0 to 100.
Higher scores reﬂect better performance.
2.3.3. Schizophrenia Cognition Rating Scale (SCoRS)
The SCoRS is an interview-based measure of cognitive impairment
with questions aimed at the degree to which this impairment affects
day-to-day functioning. Each item is rated on a scale ranging from 1 to
4with higher scores reﬂecting a greater degree of impairment, with an-
chor points for all levels of the 4-point scale. The anchor points for each
item focus on the degree of impairment in that ability and the degree to
which the deﬁcit impairs day-to-day functioning. Raters considered
cognitive deﬁcits only and attempted to rule out non-cognitive sources
of the deﬁcits. Final scores for the SCoRS best judgment ratings generat-
ed by an interviewer who had administered the scale to the patient and
informant (family member, friend, social worker, etc.). A simple sum of
the 20 SCoRS items was used as the dependent variable (Keefe et al.,
2015a).
2.3.4. Real-world functional outcomes
The rating scale employed was the Speciﬁc Levels of Functioning
(SLOF) (Schneider and Struening, 1983). The original SLOF is a 43-
item informant-rated 5-point Likert scale of a person's behavior and
functioning thatwas abbreviated to assess the following domains: Inter-
personal Functioning, Everyday Activities, and Vocational Functioning. The
dependent variablewas the average score for the items in each subscale
(range 1–5), leading to a summed total score that could range from 3 to
15 for each participant, with higher scores indicating better functioning.The same informant who provided information for the SCoRS served as
the SLOF informant.2.3.5. Clinical symptom severity ratings
Severity of psychotic and negative symptoms in patients was
assessed using the Positive and Negative Syndrome Scale (Kay et al.,
1987). This 30-item scale is widely used to rate clinical symptoms in
treatment trials in schizophrenia.
All subjects completed the VRFCAT, UPSA-VIM, and the MCCB at
Visit 1. Patients also received SCoRS and SLOF ratings and were rated
with the PANSS at Visit 1. All subjects who participated in the initial
assessment were asked to return within 7 to 14 days of initial testing
for a second assessment with the UPSA-VIM and an alternate version
of the VRFCAT. Time 1 and time 2 versions of the VRFCATwere random-
ly assigned to patients and controls in equal numbers across the 6
forms, with no one tested with the same form twice. Key outcome
measures for the VRFCATwere the total time to complete all objectives,
progressions, and errors. Equal numbers of healthy controls and schizo-
phrenia patients were scheduled to be tested with each form at each
assessment.2.4. Statistical analyses
The VRFCAT total time, total errors, and progression scores were
transformed into standardized T-scores for purposes of analyses. Re-
gression models containing age and gender as predictors were ﬁt to
data from the healthy control sample which were trimmed to remove
the 4 highest and 4 lowest scores. Predicted scores for each schizophre-
nia subject were calculated using parameter estimates from these re-
gression models and subtracted from their actual scores to yield a
residual value. The sign of the residuals was adjusted so that higher
values reﬂected better performance and were then transformed into
T-scores using the SD of the residuals from the regression models on
the healthy control sample. The resulting T-scores reﬂect how each of
the schizophrenia subjects performed relative to expectations for a
healthy control subject of the same age and gender in this sample.
Raw scores for the MCCB subtests were converted to T-scores and a
composite score through the use of the MCCB scoring program. Scores
on the UPSA-VIM were standardized with a range of 0 to 100. Totals
for the SCoRS, SLOF (as modiﬁed), and PANSS were used in analyses.
Group comparisons were made with t-tests and the magnitude of
the effect size differenceswas calculated with Cohen's d. Retest stability
wasmeasured with intra-class correlation coefﬁcients (ICC). Test-retest
practice effects were determined with Cohen's d and t-tests. The rela-
tionships among themeasureswere calculatedwith Pearson correlation
coefﬁcients and multiple regression analyses. Since the correlations be-
tween individual SCoRS items and individual SLOF domains were based
on single-item SLOF Likert-scales, they were based upon Spearman cor-
relation calculations. All other correlations used Pearson correlations
calculations.3. Results
The study sample included 167 patients with schizophrenia (of
whom 158 have complete data on all VRFCAT measures) and 166
healthy controls. One extreme outlier (7 SD below the mean total
time) in the healthy control groupwas eliminated from all analyses. De-
scriptive characteristics for the resulting 323 participants in the two
samples are presented in Table 2. As can be seen in the table, age, sex,
primary language, race and ethnic characteristics, and maternal educa-
tion did not differ across the patient and control samples. Patients had
less education, were slightly more likely to rate themselves as less com-
fortable with the computer, and were more likely to be unemployed.
Table 2
Descriptive information on the participant samples.
Healthy controls Schizophrenia patients t p
N M SD N M SD
Age 165 42.6 13.94 158 43.6 11.85 −0.72 0.47
Years of education 165 14.7 2.41 157 12.8 1.99 7.77 b0.001
Mother's education 155 12.9 2.98 142 12.5 3.33 1.18 0.24
% (N) % N Χ2 p
Male 53 (88) 56 (88) 0.18 0.67
Unemployed 33 (54) 85 (135) 92.40 b0.001
Comfortable with computer 97 (160) 89 (140) 8.53 0.004
Hispanic 18 (29) 19 (30) 0.11 0.74
English primary language 95 (157) 96 (151) 0.03 0.86
Race
Caucasian 56 (92) 47 (75) 3.33 0.19
African American 38 (63) 48 (76)
Other 6 (10) 4 (7)
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Table 3 presents performance on the MCCB, the UPSA-VIM, and the
T-scores for the VRFCAT variables (total time, total errors, and progres-
sion) for both participant samples, and clinician ratings on the SCoRS,
SLOF and PANSS. As can be seen in the table, healthy control participants
performed better than the schizophrenia patients on the MCCB, the
UPSA-VIM, and all three indices from the VRFCAT, with all differences
signiﬁcant at p b 0.001. The magnitude of differences between the
groups was very large and very similar for all outcomes, with Cohen's
d = 1.21 for the VRFCAT time to completion, d = 1.22 for the MCCB
and d = 1.16 for the UPSA-VIM. For the VRFCAT total errors and pro-
gression, the group differences were smaller, but still reﬂected large ef-
fect sizes. One patient performed at greater than one standard deviation
better than the healthy control mean on the VRFCAT at the ﬁrst assess-
ment, while 3 patients did so on the UPSA-VIM, suggesting that ceiling
effects were rare for both measures.3.2. Test-retest stability and practice effects
In Table 4, we present the test-retest stability and practice effects for
the VRFCAT and UPSA-VIM. The UPSA-VIM had a signiﬁcantly larger
practice effect for both participant samples. The test-retest coefﬁcients
for the VRFCAT total time and UPSA-VIM scores were consistent, espe-
cially for patients, with errors and forced progressions having lower
test-retest reliability. No VRFCAT variables evidenced any substantial
changes associated with re-testing in either sample. The lack of retestTable 3
Performance on VRFCAT, MCCB, and UPSA and clinical variables at Visit 1.
Healthy controls Schizophrenia
Patients
Cohen's d
N M SD N M SD
MCCBa 163 44.0 13.19 155 28.1 12.91 1.22
UPSA-VIMa 164 83.2 9.03 158 71.0 11.85 1.16
VRFCAT total timeb 165 49.7 11.48 158 32.5 16.59 1.21
VRFCAT total errorsb 165 49.4 11.61 158 37.7 22.40 0.66
VRFCAT progressionb 165 49.7 10.16 158 40.5 13.64 0.77
SCoRS interviewer ratingsc – – – 156 38.2 9.88
SLOF interviewer total scored – – – 158 11.1 1.64
PANSS total scores – – – 158 71.6 21.93
Notes: All Cohen's d are signiﬁcant at p b 0.001.
a Maximum total score is 100;
b T score: Mean = 50, SD = 10 in healthy controls;
c Maximum score is 80, higher scores are worse;
d Maximum score is 15.differences suggests similar levels of difﬁculty for the 6 versions of the
VRFCAT.
3.3. Correlations with other performance-based measures
Table 5 contains Pearson correlations between the VRFCAT outcome
measures, the UPSA-VIM total score and the MCCB composite score for
healthy controls and patients with schizophrenia. Even though the
VRFCAT is a computerized measure, and thus has a different method
than the UPSA-VIM and 9 of the 10 tests of the MCCB, the UPSA-VIM
and VRFCAT demonstrated similar correlations with the MCCB for the
healthy controls (0.74 vs. 0.68, z = 1.32, p = 0.19). In the patient
group, the correlation between the MCCB and UPSA-VIM was larger
than the r=0.65 usually reported in the literature andwas signiﬁcantly
greater than the VRFCAT-MCCB correlation (0.70 vs. 0.57, z = 2.41, p=
0.016). All correlations between the VRFCAT measures, the MCCB com-
posite, and the UPSA-VIM were signiﬁcant (p b 0.001) in patients and
controls, although correlations for VRFCAT errors and progression
with the UPSA-VIM and MCCB were smaller in magnitude.
3.4. Correlations with interview-based functional and cognitive outcomes
For patients with schizophrenia, the UPSA-VIM and all three VRFCAT
measures (total time, total errors, and occurrence of progression) were
signiﬁcantly correlated with better everyday functioning on the SLOF
and lower ratings of cognitive impairment on the SCoRS (Table 6). The
sum of the individual items of the SCoRS was signiﬁcantly correlated
with the SLOF total score (r= 0.57, p b 0.001). Almost all SCoRS items
had correlations N0.20 (p b 0.01)with the SLOFdomain scores (See Sup-
plemental Table 1).
3.5. Tolerability for patients
Subjects on average found theVRFCAT to be highly realistic, pleasant
to take, easy to use, and found the instructions clear (Supplemental
Table 2). Although all subjects rated the task highly with respect to
ease of use and understandability of instructions, these ratings were
higher for healthy controls.
3.6. Equivalence of forms
The next analyses examined the equivalence of the 6 forms of the
VRFCAT.We focused on the total time variable because of its correlation
with the MCCB and its greater sensitivity to diagnosis. Supplemental
Fig. 1 presents differences between healthy control and patient samples
on the 6 forms of the VRFCAT at both visits presented as Cohen's d. As
can be seen in the ﬁgure, the effect size for separation of controls and
Table 4
Test-retest stability and practice effects for UPSA-VIM and VRFCAT variables.
Visit 1 Visit 2
HC (N = 165) SZ (N = 158) HC (N = 159) SZ (N = 151) Cohen's d ICC
M SD M SD M SD M SD HC SZ HC SZ
VRFCAT time 49.7 11.48 32.5 16.59 50.9 11.52 31.8 17.62 0.10 −0.04 0.65 0.81
VRFCAT errors 49.4 11.61 37.6 22.40 49.8 12.94 36.7 22.07 0.03 −0.04 0.54 0.65
VRFCAT progressions 49.7 10.16 40.5 13.64 50.3 10.51 40.8 13.58 0.06 0.03 0.29 0.61
UPSA-VIM 83.2 9.03 71.0 11.85 86.7 9.07 74.5 12.07 0.39*** 0.35*** 0.75 0.78
HC, healthy controls.
SZ, schizophrenia patients.
⁎⁎⁎ p b .001.
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ences were statistically signiﬁcant (all d N 0.9; all n ≥ 47; all p ≤ 0.001),
although Cohen's d was smaller at the ﬁrst assessment for forms 1 and
6. These results suggest that the 6 forms of theVRFCAT, administered ei-
ther ﬁrst or second, are associated with substantial separation of the
two groups.
Also, we examined the correlations between the UPSA-VIM and the
MCCB and each form of the test at the ﬁrst assessment for both the total
sample and just the schizophrenia patients. As can be seen in supple-
mental Fig. 2, the correlations were quite similar for total time and
UPSA-VIM scores across the different forms of the VRFCAT. Similarly,
the correlations for each form of the VRFCAT and the composite MCCB
score were comparable to each other and essentially identical to the
UPSA-VIM correlations for every form. Analogous results were found in
the patient sample, although the correlationswere approximately 10per-
centage points lower overall. A two-wayAnalysis of Variance (ANOVA) of
time to completion was used to compare the different VRFCAT forms for
the patients and controls at baseline. An overall difference between forms
was noted (F5,322=3.28, p=0.007) and pairwise comparisons using the
Tukey-Kramer adjustment for multiple comparisons revealed signiﬁcant
differences (p ≤ 0.05) between form 1 with the lowest LSMean T-scores
(37.6 ± 1.82) and forms 2 and 5 with the highest (45.1 ± 1.92 and
45.7 ± 1.87, respectively). A test for the interaction of subject group
and form was nonsigniﬁcant (F5,322 = 0.20, p= 0.96).
4. Discussion
The Virtual Reality Functional Capacity Assessment Tool (VRFCAT), a
computerized test involving several functionally relevant cognitive
challenges, was found to separate healthy controls and schizophrenia
patients and to manifest convergent validity with the MCCB, the
SCoRS, and the UPSA-VIM, the primary outcome measures previously
used in successful treatment studies of cognitive impairment in schizo-
phrenia. The test was reported to be easily tolerable for patients, and
required about 30 min to complete.
The VRFCAT compared favorably with the test most frequently used
as a co-primary measure in schizophrenia clinical trials, the UPSA. In
this study, the version of the UPSA with the best psychometricTable 5
Pearson correlations between VRFCAT variables and MCCB and UPSA scores in healthy
controls (N= 162) and schizophrenia patients (N= 155).
1 2 3 4 5
1. MCCB – 0.74 0.68 0.50 0.36
2. UPSA-VIM 0.70 – 0.58 0.50 0.39
3. VRFCAT total time 0.57 0.56 – 0.74 0.59
4. VRFCAT total Errors 0.39 0.41 0.70 – 0.72
5. VRFCAT total progressions 0.45 0.43 0.71 0.65 –
Note: Healthy controls above the diagonal. Schizophrenia patients are below. All correla-
tions are signiﬁcant at p b 0.001.
Sample size restricted to those subjects with data available for all 5 measures.
Bold numbers are used to differentiate the patients from the controls.characteristics from previous studies, the UPSA-VIM, was used. Test-
retest reliability of the VRFCATwas similar to theUPSA-VIM,with small-
er practice effects than the UPSA-VIM. These practice effect differences
are likely due to the 6 alternate forms of the VRFCAT. All 6 of these
formsmanifested similar separation of healthy controls and schizophre-
nia patients, as well as correlations with the UPSA-VIM and MCCB that
were essentially identical across all 6 forms. Further, 3 patients per-
formed 1 SD above the mean for HC on the UPSA, and 1 patient did so
with the VRFCAT, suggesting that all or almost all patients would have
room to improve during the course of a treatment study.
In contrast to interview-based measures of cognition, the VRFCAT is
purely performance-based and does not require an informant. While
interview-basedmeasures of cognition have good psychometric charac-
teristics (Keefe et al., 2006a, 2015a; Ventura et al., 2013), the SCoRS has
far weaker correlations with objective performance-based measures
and is less sensitive to the effects of treatments that improve perfor-
mance on the MCCB when informants are not available (Keefe et al.,
2015a). Performance-based functional capacity measures such as the
VRFCAT do not require informants and thusmay help to reduce the bur-
den on investigators and participants in clinical trials.
In this study, completion timewas the variablemost robustly associ-
ated with MCCB and UPSA-VIM scores as compared to indices of poor
performance such as errors and progressions. In the VRFCAT procedure,
more errors and more progressions lead to longer time for completion.
A time variable as an outcome is common in neuropsychological assess-
ments. For instance, rapid completion with concurrent error correction
by testers is the key performance demand in three of the MCCB tasks:
Trails A, BACS symbol coding, and verbal ﬂuency. In fact, tests with
time-based dependent variables have repeatedly been found to be the
strongest correlates of composite neuropsychological performance
(Keefe et al., 2006b), performance on measures of functional capacity
(McClure et al., 2007), and everyday outcomes (Harvey et al., 2009).
These tests have long been known to have small but systematically de-
tectable practice effects (Goldberg et al., 2010; Keefe et al., 2008) aswell
as substantial importance for prediction of functioning across neuropsy-
chiatric conditions (Jaeger et al., 2006).
There are some limitations of this research design and dataset. First,
it was not possible to perform a test-retest study of individual forms
(i.e., form 1 at both time 1 and 2) with the current sample size; weTable 6
Correlations with convergent validity variables for patients only.
Schizophrenia Cognition Rating
Scale (SCoRS)
Speciﬁc Levels of
Functioning (SLOF)
(N= 156) (N= 158)
UPSA-VIM −0.24⁎⁎ 0.25⁎⁎
VRFCAT total time −0.29⁎⁎⁎ 0.22⁎⁎
VRFCAT total errors −0.28⁎⁎⁎ 0.29⁎⁎⁎
VRFCAT progression −0.29⁎⁎⁎ 0.17⁎
⁎ Signiﬁcance of correlations: p b 0.05.
⁎⁎ Signiﬁcance of correlations: p b 0.01.
⁎⁎⁎ Signiﬁcance of correlations: p b 0.001.
95R.S.E. Keefe et al. / Schizophrenia Research 175 (2016) 90–96were more interested in exploring alternative forms for their equiva-
lence. Second, the correlations of the SCoRS and SLOF with the UPSA-
VIM and VRFCAT were relatively small. This pattern of correlations is
consistent with previous literature on the relationship of performance-
basedwith interview-based outcomes (Green et al., 2008, 2011),where-
by method variance contributes so robustly to the strength of the
relationship among measures that it outweighs the relationship
among constructs. Third, we did not assess patients with acute symp-
toms, so the practicality of using the VRFCAT in exacerbated patients is
not known. Finally, we did not attempt to assess the treatment sensitiv-
ity of the VRFCAT in this phase of its development. It is important to note
that the MCCB and the UPSA-VIM were also developed without this in-
formation available at the time of their development. These measures
have each demonstrated sensitivity to treatment effects with both phar-
macological and cognitive remediation interventions (Bowie et al.,
2012; Fisher et al., 2009; Green et al., 2008; Javitt et al., 2012; Keefe
et al., 2015b; Mahableshwarkar et al., 2015). Future treatment studies
using the VRFCAT as a treatment target will test its sensitivity.
In summary, an immersive virtual reality functional capacity assess-
ment with 6 forms was found to manifest high levels of reliability and
convergent validity across the forms. Patient experience with com-
puters did not pose a barrier to completion and the psychometric char-
acteristics of the measure meet all of the established criteria for
acceptance. The potential ﬂexibility of the computerized format is also
a beneﬁt, in that the test has the potential for being delivered remotely
as well as being modiﬁed for cross-cultural usage in geographical re-
gions where computer use, public transportation, and grocery stores
are common.
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